Advisory Research Inc. Invests $1.04 Million in AxoGen, Inc. (NASDAQ:AXGN)

Advisory Research Inc. bought a new position in shares of AxoGen, Inc. (NASDAQ:AXGN – Get Rating) during the third quarter, according to its most recent filing with the SEC. The fund bought 87,078 shares of the medical equipment provider’s stock, valued at approximately $1,038,000. Advisory Research Inc. owned 0.21% of AxoGen at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in AXGN. HighMark Wealth Management LLC raised its stake in shares of AxoGen by 851.1% during the 3rd quarter. HighMark Wealth Management LLC now owns 2,235 shares of the medical equipment provider’s stock worth $27,000 after purchasing an additional 2,000 shares during the period. Almanack Investment Partners LLC. bought a new stake in shares of AxoGen during the 3rd quarter worth $27,000. Lazard Asset Management LLC raised its stake in shares of AxoGen by 1,282.6% during the 1st quarter. Lazard Asset Management LLC now owns 5,088 shares of the medical equipment provider’s stock worth $40,000 after purchasing an additional 4,720 shares during the period. Royal Bank of Canada raised its stake in shares of AxoGen by 610.2% during the 3rd quarter. Royal Bank of Canada now owns 6,129 shares of the medical equipment provider’s stock worth $74,000 after purchasing an additional 5,266 shares during the period. Finally, Tower Research Capital LLC TRC raised its stake in shares of AxoGen by 139.2% during the 3rd quarter. Tower Research Capital LLC TRC now owns 8,909 shares of the medical equipment provider’s stock worth $106,000 after purchasing an additional 5,184 shares during the period. 76.22% of the stock is currently owned by institutional investors.

AxoGen Trading Up 12.0 %

Shares of AxoGen stock opened at $8.43 on Wednesday. AxoGen, Inc. has a 52-week low of $6.87 and a 52-week high of $13.66. The stock’s 50-day simple moving average is $9.26 and its 200 day simple moving average is $10.35. The stock has a market capitalization of $356.50 million, a P/E ratio of -12.40 and a beta of 0.54. The company has a debt-to-equity ratio of 0.65, a quick ratio of 3.54 and a current ratio of 4.35.

Wall Street Analysts Forecast Growth

Separately, StockNews.com upgraded AxoGen from a “hold” rating to a “buy” rating in a research note on Thursday, November 17th.

Insider Activity at AxoGen

In related news, CFO Peter J. Mariani sold 14,320 shares of the business’s stock in a transaction dated Tuesday, January 31st. The stock was sold at an average price of $9.55, for a total value of $136,756.00. Following the sale, the chief financial officer now directly owns 55,555 shares in the company, valued at approximately $530,550.25. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In other AxoGen news, CFO Peter J. Mariani sold 20,939 shares of AxoGen stock in a transaction dated Thursday, January 26th. The stock was sold at an average price of $9.90, for a total transaction of $207,296.10. Following the completion of the transaction, the chief financial officer now owns 42,108 shares of the company’s stock, valued at approximately $416,869.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Peter J. Mariani sold 14,320 shares of AxoGen stock in a transaction dated Tuesday, January 31st. The shares were sold at an average price of $9.55, for a total value of $136,756.00. Following the transaction, the chief financial officer now directly owns 55,555 shares of the company’s stock, valued at approximately $530,550.25. The disclosure for this sale can be found here. 7.51% of the stock is currently owned by company insiders.

AxoGen Profile

(Get Rating)

Axogen, Inc engages in the development and market of surgical solutions for peripheral nerve regeneration and repair. It also provides products and education to improve surgical treatment algorithms for peripheral nerve damage or discontinuity. The firm’s products include avance nerve graft, axoguard nerve connector, axoguard nerve protector, avive soft tissue membrane, acroval neurosensory and motor testing system, and axotouch two-point discriminator.